BioMarin Pharmaceutical (BMRN) vs ImmunityBio (IBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmunityBio (IBRX) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 290.0% versus a gain of 0.9%. Over five years, IBRX leads with a +4.8% price change compared with -27.3% for BMRN. BioMarin Pharmaceutical is the larger company by market cap ($10.69 billion vs $10.33 billion), about 1.0 times the size, while ImmunityBio is growing revenue faster (+668.3% vs +12.9%).
BioMarin Pharmaceutical converts more of its revenue into profit, with a net margin of 10.8% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRN | IBRX |
|---|---|---|
| Share price | $55.20 | $9.75 |
| Market cap | $10.69B | $10.33B |
| 1-day change | -1.81% | +0.62% |
| YTD return | -7.12% | +392.42% |
| 1-year return | +0.91% | +290.00% |
| 5-year return | -27.26% | +4.84% |
| P/E ratio (TTM) | 149.19 | — |
| Forward P/E | 8.34 | — |
| EPS (TTM) | $0.37 | $-0.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.22B | $113.29M |
| Revenue growth (YoY) | +12.87% | +668.31% |
| Net income (latest FY) | $348.90M | $-351.40M |
| Gross margin | 77.73% | 99.34% |
| Operating margin | 12.71% | -226.00% |
| Net margin | 10.83% | -310.18% |
| 52-week high | $70.98 | $12.43 |
| 52-week low | $49.26 | $1.95 |
| Distance from 52-week high | -22.23% | -21.56% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +65.98% | +30.77% |
| Average volume | 2.01M | 10.27M |
| Shares outstanding | 193.57M | 1.06B |
| Employees | 3,221 | 684 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed BMRN by 289.1 percentage points over the past year.
- BioMarin Pharmaceutical is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +12.87%).
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
BMRN vs IBRX FAQ
Which is bigger, BioMarin Pharmaceutical or ImmunityBio?
BioMarin Pharmaceutical (BMRN) is larger, with a market capitalization of $10.69B compared with $10.33B for ImmunityBio (IBRX).
Which stock has performed better over the past year, BMRN or IBRX?
IBRX returned +290.00% over the past 12 months, compared with +0.91% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Are BioMarin Pharmaceutical and ImmunityBio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BioMarin Pharmaceutical and Biotechnology: Biological Products (No Diagnostic Substances) for ImmunityBio.